Advertisement
Table 13 Selected neoplastic and non-neoplastic lung effects in 2 year inhalation studies of male and female F344/N rats and B6C3F1 mice exposed to nickel subsulphide, nickel oxide and nickel sulphate hexahydrate [30–32]; and Wistar rats exposed to nickel metal powder [35]
| F344/N rats | B6C3F 1 mice | |||
|---|---|---|---|---|
| Ni species, dose and lung effects | Male | Female | Male | Female |
| Nickel subsulphide: | ||||
| Dose in % of MTDa, b | (0, 15, 100) | (0, 15, 100) | (0, 50, 100) | (0, 50, 100) |
| Chronic active inflammation rate | (9/53, 53/53, 51/53) | (7/53, 51/53, 51/53) | (1/61, 52/59, 53/58) | (1/58, 46/59, 58/60) |
| Macrophage hyperplasia rate | (9/53, 48/53, 52/53) | (8/53, 51/53, 52/53) | (6/61, 57/59, 58/58) | (5/58, 57/59, 60/60) |
| Alveolar/bronchiolar adenoma or carcinoma rate | (0/53, 6/53, 11/53) | (2/53, 6/53, 9/53)f | None | None |
| Nickel oxide: | ||||
| Dose in % of MTDc | (0, 25, 50, 100) | (0, 25, 50, 100) | (0, 25, 50, 100) | (0, 25, 50, 100) |
| Chronic inflammation rate | (28/54, 53/53, 53/53, 52/52) | (18/53, 52/53, 53/53, 54/54) | (0/57, 21/67, 34/66, 55/69) | (7/64, 43/66, 53/63, 52/64) |
| Alveolar/bronchiolar adenoma or carcinoma rate | (1/54, 1/53, 6/53, 4/52)f | (1/53, 0/53, 6/53, 5/54) | None | (6/64, 15/66, 12/63, 8/64) |
| Nickel sulphate hexahydrate: | ||||
| Dose in % of MTDd | (0, 25, 50, 100) | (0, 25, 50, 100) | (0, 25, 50, 100) | (0, 25, 50, 100) |
| Chronic active inflammation rate | (14/54, 11/53, 42/53, 46/53) | (14/52, 13/53, 49/53, 52/54) | (1/61, 2/61, 8/62, 29/61) | (1/61, 7/60, 14/60, 40/60) |
| Macrophage hyperplasia rate | (7/54, 9/53, 35/53, 48/53) | (9/52, 10/53, 32/53, 45/54) | (6/61, 9/61, 35/62, 59/61) | (7/61, 24/60, 53/60, 59/60) |
| Neoplastic effects | None | None | None | None |
| Wistar rats | ||||
| Nickel metal: | ||||
| Dose in % of MTDe | (0, 25, 100) | (0, 25, 100) | ||
| Chronic inflammation rate | (14/50, 44/50, 41/50) | (16/50, 45/50, 45/54) | ||
| Neoplastic effects | Noneg | Noneg | ||
